leuvectin

leuvectin

Oncology An agent for treating metastatic melanoma, renal cell carcinoma, and sarcoma
References in periodicals archive ?
Vical's two lead product candidates, Allovectin-7 and Leuvectin, both involve direct injection of genetic material into tumors or surrounding tissue using lipids to facilitate delivery.
Leuvectin, which uses a lipid-DNA complex to stimulate an immune response against cancer cells, is in Phase II testing in patients with prostate cancer.
Avodart, Zoladex, Proscar, Casodex, Taxotere, Satraplatin, Plenaxis, EULEXIN, Trelstar Depot, Trelstar LA, Viadur, Gleevec, Avastin, Herceptin, Atrasentan, Acapodene, Actimid, OSI-461, Revimid, Eladem, GTI-2501, ILX-651, calcitrol, Genasense, Provenge , GVAX, SGN-15, Thalomid, Velcade, Lupron Depot, Histrelin, Eligard, ILX651, Vitaxin, J591, CG7870, BBR-3576, PCK3145, Leuvectin, Leuprolide, ProMaxx-100, Osaterone, Prinomastat, BLP25, Metaret, Chimax, Drogenil, Flutamide, EULEXIN, Onconase, IM862, MDX-010, Erbitux, Eladem, GTI-2040, Apomine, Eflornithine, Doxil, GTI-2501, Thalidomide, TG4010, KRX-0401, Yondelis, TRICOM Vaccine, Zarnestra
We believe this patent , which covers the use of gene-based IL-2 therapy for all tumor types, broadens our protection of potential market exclusivity for Leuvectin.
Gillespie provided an overview of clinical trials with nonviral gene therapies, featuring Vical's lead programs Allovectin-7, which is in registration trials for metastatic melanoma, and Leuvectin, which is in late Phase II trials for metastatic kidney cancer.
We look forward to a review of preliminary data from these trials and from our Leuvectin trial for patients with metastatic renal cell carcinoma at the upcoming annual meeting of the American Society of Clinical Oncology.
In addition, Vical is currently conducting Phase II clinical trials in patients with prostate cancer using Leuvectin, a gene-based immunotherapy that delivers IL-2 locally.
president and chief executive officer of Vical, presented the company's Phase I/II clinical experience with Leuvectin in the treatment of prostate cancer.